Seattle Genetics has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the FDA for MN-IC, an ADC for solid tumors.
Under the terms of the ADC collaboration agreement, Bayer has rights to use Seattle Genetics’ ADC technology with antibodies against MN. Bayer is responsible for research, product development, manufacturing and commercialisation of all products under the collaboration.
Seattle Genetics receives material supply and annual maintenance fees as well as research support payments for any assistance provided to Bayer in developing ADC products.
Eric Dobmeier, chief business officer of Seattle Genetics, said: “We are pleased with the continued progress by our collaborators in advancing ADCs spanning a range of oncology indications and settings. MN-IC will be the third new ADC program utilizing our technology to advance into clinical trials during the past 12 months. In addition to generating revenue, these collaborator programs broaden the clinical experience with our ADC technology and build on our understanding of its potential in the treatment of serious diseases.”